title: [Feasability of the dose adjustment of continuous infusion administration over 120 hours of 5-fluorouracil associated with cisplatin].
abstract: Therapeutic monitoring of 120 hours continuous 5-fluorouracil associated with cisplatin. For 31 patients treated by continuous 5-fluorouracil with cisplatin, a therapeutic monitoring of 5-fluorouracil is performed, based on the 48 first hours area under the curve (AUC) and the total AUC. The 5-fluorouracile taylorization allows to reduce some toxicity's while preserving an efficiency (objective responses 42%). Many patients are considered with potentially low 5-fluorouracile clearance. Dose reductions of 5-fluorouracile are frequent, reach 50% during the third cure and allow the achievement of targeted AUC. The role of cisplatin in this necessary reduction of dose is unknown.
authors.affiliation: Centre GF-Leclerc, Dijon, France.
authors.forename: B
authors.initials: B
authors.lastname: Coudert
authors.forename: C
authors.initials: C
authors.lastname: De Gislain
authors.forename: J L
authors.initials: JL
authors.lastname: Beltramo
authors.forename: B
authors.initials: B
authors.lastname: Guigues
authors.forename: F
authors.initials: F
authors.lastname: Mayer
authors.forename: Y
authors.initials: Y
authors.lastname: Bruchon
authors.forename: J M
authors.initials: JM
authors.lastname: Riedinger
authors.forename: P
authors.initials: P
authors.lastname: Fargeot
authors.forename: M
authors.initials: M
authors.lastname: Dumas
authors.forename: J
authors.initials: J
authors.lastname: Guerrin
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D019540:Area Under Curve; D001984:Bronchial Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002945:Cisplatin / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D016903:Drug Monitoring; D004357:Drug Synergism; D005472:Fluorouracil / Q000008:administration & dosage* / Q000009:adverse effects / Q000378:metabolism; D006258:Head and Neck Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007262:Infusions, Intravenous; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D016896:Treatment Outcome
chemical_list: D002945:Cisplatin; D005472:Fluorouracil
vernacular_title: Faisabilité de l'adaptation de la posologie du 5-fluorouracile administré en perfusion continue de 120 heures associé au cisplatine.